180 Wealth Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

180 Wealth Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,940	Closed	-$345K	–	390
2021 Q1	$345K	Buy	1,940 +357	+23%	+$55.2K	0.09%	220
2020 Q4	$251K	Sell	1,583 -673	-30%	-$86.5K	0.07%	256
2020 Q3	$280K	Buy	2,256 +286	+15%	+$30.9K	0.11%	193
2020 Q2	$215K	Buy	+1,970	New	+$209K	0.09%	230

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

180 Wealth Advisors's ALXN Position: Q2 2021 in Review

180 Wealth Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 1,940 shares — an estimated $345K sold.

180 Wealth Advisors first reported a position in ALXN in Q2 2020 and held it in 4 quarters. The position peaked at $345K in Q1 2021. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

180 Wealth Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
180 Wealth Advisors sold 1,940 Alexion Pharmaceuticals shares in Q2 2021, an estimated $345K.
180 Wealth Advisors first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 4 quarters.
180 Wealth Advisors's Alexion Pharmaceuticals position peaked at $345K in Q1 2021.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on 180 Wealth Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.